


OnePass Medical is transforming **biopsy procedures to include treatments**, enabling physicians to treat patients in one pass. The company is achieving this by means of its **multi-needle aspiration biopsy device** (vs. current ones which have only one needle), which enables to focus the treatment on the target area.



### 1<sup>st</sup> Product – Saving Lives in Biopsies

Current EUS-FNA/B (Endoscopic Ultrasound guided Fine Needle Aspiration Biopsy) devices use only **one needle**. As tumors are heterogenic, they **do not** diagnose pancreas cancer in **20-40%** of biopsies, resulting in a **95% death** rate in these cases.

OnePass Medical's disposable **multi-needle EUS-FNA/B device** enables taking biopsies simultaneously in one pass from **five different locations** in a tumor, substantially reducing false negative results and thereby **saving lives**.

### 2<sup>nd</sup> Product – Saving More Lives in Biopsy Treatments

By simply adding an algorithm module, OnePass Medical's multi-needle EUS-FNA/B device will be transformed into a **therapeutic delivery platform**, enabling to destroy tumorous cells during the biopsy procedure itself.

### Additional Benefits to Saving Lives

- **Increases revenues:** By reducing procedure complexity, it allows more physicians to offer this procedure to their patients and in less time.
- **Saves costs:** Currently, needles are kinked in 15% of cases and the extra needles are not reimbursed. These costs are eliminated.
- **Competitive pricing:** High-quality product offering a better clinical outcome at a highly competitive price when compared to other devices on the market.

### Go-to-Market Strategy

Working with **distributors**, OnePass Medical will enter the market in these stages:

1. **Biopsies** – Focusing on the USA and Europe, which hold two thirds of the EUS FNA/B and prostate biopsy markets, estimated to reach **\$1 billion** in 2022.
2. **Therapeutic** – While its platform could be used to deliver various treatments (e.g. chemotherapy or local biological treatments), OnePass Medical is initially focusing on the **\$2.5 billion** RF ablation market in 2022.

### Investment Sought

OnePass Medical is raising **\$6 million** (of which it is securing \$2 million in non-diluting matching funds from the IIA), mainly for sales of its first product and for bringing the complementary therapeutic platform into the market.

### Company Background

Founded: 2018.

Funds-to-date: Nearly **\$1.2 million** from G.O (an IIA incubator) and co-founders.

### Milestones

- Completed the development of its first product and is ready for production to support its sales activities.
- Built strong IP portfolio - 1<sup>ST</sup> patent issued by the USPTO.
- Initiated sales - 1<sup>ST</sup> sales agreement is already in place.

### Team



**Jacob BenArie**

CEO & Co-founder (MBA)

Experience: Managing Director, Q2Pharma; CEO, Betalin Therapeutics; CEO, Beta-Stim; CEO, Orgenesis (Nasdaq: ORGS).



**Prof. Jesse Yishai Lachter**

Chief Medical Officer & Inventor

Experience: Gastroenterologist, prof. of medicine, and Head of EUS Service, Rambam Health Care Campus.



**Eli Ben Porat**

Head of Biz Dev (MBA)

Experience: VP Business Development & Sales, Nrgene; Director of Biz Dev, Zeraim Gedera (sold to Syngenta for \$95 million).